|

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

RECRUITINGEarly 1Sponsored by Children's Hospital of Philadelphia
Actively Recruiting
PhaseEarly 1
SponsorChildren's Hospital of Philadelphia
Started2013-12
Est. completion2027-01
Eligibility
Healthy vol.Accepted
Locations1 site

Summary

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+/CD19+ depletion.
2. Patients with the following transplantable diseases:

   Non-malignant diseases:

   Metabolic storage diseases correctable by HSCT, Bone marrow failure syndromes, Immunodeficiencies/immune dysregulation syndromes/including HLH, Hemoglobinopathies correctable and requiring HSCT, and Other diseases treated with HSCT/Other non-malignant blood, metabolic, or immune disorders for which HSCT has been recommended

   Malignant diseases:

   Acute leukemias, Chronic leukemias, Lymphomas, Myelodyplastic syndrome
3. Signed informed consent
4. Lansky or Karnofsky performance ≥60
5. Hematologic and Organ Function per current institutional SOP.
6. Infectious Evaluation as per current institutional SOP.
7. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP
8. In cases that are deemed clinical emergencies (primary or secondary graft failure, severe marrow suppression), the above status criteria will be waived.
9. Patients must have an identified living donor

   * Donor selection will comply with 21 CFR 1271
   * Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10/10 match, a 9/10 match, or an 8/10 match if one of the mismatches is at DQB1
   * Related donor suitable for mobilization infectious disease criteria as per SOP, including HIV, HepB, HepC PCR negative.
   * CHOP BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.
   * Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.
   * The donors selected for this IND will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors; NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases

Exclusion Criteria:

1. Uncontrolled bacterial, viral or fungal infections
2. Suitable, fully HLA matched sibling donor
3. Donor unable to donate peripheral stem cells
4. Pregnant participants

Conditions6

Bone Marrow Failure SyndromesCancerImmunodeficienciesImmunodysregulation Polyendocrinopathy Enteropathy X-linked SyndromeInborn Errors of MetabolismLeukemia

Locations1 site

Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Megan Atkinson215-590-2820cttsbmtintake@chop.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.